BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:40 PM
 | 
Apr 19, 2007
 |  BC Extra  |  Company News

Novartis in-licenses Antisoma's AS1404

Antisoma (LSE:ASM) granted Novartis (NVS; SWX:NOVN) exclusive, worldwide rights to AS1404 to treat various cancers. ASM will receive $75 million up front and is eligible for $815 million in milestones, plus royalties....

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >